Appropriate classification of disease is essential not only to the study of its causation and pathophysiology but to selection of appropriate treatment. The development of morphologic and immunologic methods to classify leukemia have been largely driven by the need to select treatment as effective agents have become available since Lissauer's success with arsenic in myeloid leukemia (Berl Klin Wochenschr 2: 403, 1865) and Farber et al's with antifolates in lymphoid leukemia (N Engl J Med 238: 787, 1948) .
The definition of acute lymphoid leukemia (ALL) as a genetic disorder of hematopoiesis and recognition that chromosomal numbers and non-random rearrangements of ALL cells correlated with biological and clinical features and curative response to treatment prompted the hypothesis that ALL might be classified and treated according to genotype (Pinkel D, Cancer 59: 1683 , 1987 . From 1987 to 1994, 151 children with ALL of all types were registered on one of two successive protocol studies in which treatment was selected according to leukemia genotype, as determined by chromosome analysis and DNA index, and by immunophenotype, a reflection of genotype (Pinkel D, Modern Trends in Human Leukemia 8: 27, 1989; Pinkel D et al, Proc AACR 33: 211, 1992) . The majority of children were Mexican-American or AfricanAmerican. All are included in the data analysis regardless of presenting condition, adherence to the protocol or premature termination of treatment. The current estimated 5-year eventfree survival is 64% (±4%) (Figure 1 ), suggesting acceptability but no survival advantage. In addition to non-adherence and early termination of treatment, major problems were unsatisfactory chromosomal analysis and failure to identify cryptic gene rearrangements.
Recent advances in molecular identification and detection of specific ALL genotypes and in linking biological and clinical features and treatment response to genotypes allow more
Figure 1
Estimated event-free survival of all children with ALL registered in two successive protocols in which genotype and immunophenotype were used to select treatment.
precise and complete genotypic classification of ALL and a better view of their significance (Tables 1 and 2 ). It seems clear that hyperdiploidy (DNA index equal to or greater than 1.16), trisomy 4 and 10 and the fusion gene TEL-AML (ETV 6 -CBFA 2), coding a transcription factor, define a group of children with ALL who have a high cure rate on largely antimetabolite-based chemotherapy (Trueworthy R et al, J Clin Oncol 10: 606, 1992; Harris M et al, Blood 79: 3316, 1992; Rubnitz J et al, Blood 89: 1143 , 1997 . They probably can be spared the hazards of anthracyclines, alkylating agents, epipodophyllotoxins and irradiation without compromise of cure rate. It seems equally clear that ALL with a rearranged HRX (MLL) gene fused to one of several other genes or with expression of the BCR-ABL fusion gene is much less curable, regardless of the age of the patient, even with intensive chemotherapy including the more hazardous agents (Behm F et al, Blood 87: 2870 , 1996 Fletcher J et al, Blood 77: 436, 1991) . Current treatment regimens also yield low cure rates for hypodiploid ALL and for the rare but clinically distinct IL3-IGM and HLF-E2A genotypes of ALL (Pui C-H et al, Blood 72: 1170 , 1990 Meeker T et al, Blood 76: 285, 1990; Inaba T et al, Science 257: 531, 1992) .
E2A-PBX ALL is usually associated with presence of cytoplasmic immunoglobulin, a mark of less curability in the past (Crist W et al, Blood 76: 117, 1990 ). However, more recent chemotherapy programs have yielded better outcome and one study suggests that addition of high-dose cytarabine following high-dose methotrexate improves cure rate (Harris M et al, Proc Am Soc Clin Oncol 16: 515a, 1997) .
TCR gene rearrangement marks T cell leukemia, now approximately 60% curable by chemotherapy when anthracyclines, cytarabine, asparaginase and sometimes cranial irradiation are included, regardless of chromosomal abnormalities (Heerema N et al, Blood 90: 185a, 1997) . The dysregulation of c-myc accompanying the fusion of IGH, IG kappa, or IG lambda genes with the MYC gene is the genetic ear mark of B cell ALL (and lymphoma) in children. B cell ALL Table 1 Rationale of genotypic classification of ALL b ALL is a genetic disorder of hematopoiesis. b Biological and clinical features and treatment response are linked to genotype. b Genotypic classification enables design and conduct of genotype-specific clinical investigation of epidemiology, molecular leukemogenesis and measurement of residual leukemia. b Genotype-specific clinical treatment studies enhance opportunities to use maximum dosage of most effective drugs, to reduce use of drugs with hazardous sequelae and to determine optimal treatment for each genotype. b Genotypic classification facilitates design and testing of novel agents targeted to ALL-associated genes, their transcripts and their products.
More important than its utility in guiding current treatment, genotypic classification will expedite basic and clinical investigations of leukemia. was usually incurable when it was treated like B-precursor ALL but has a high cure rate when high dosages of antimetabolites and an alkylator are begun during remission induction (Patte C et al, J Clin Oncol 9: 123, 1991) . In addition, treatment of MYC-IG ALL need only be continued for 3 months rather than the 2 to 3 years required for other types of ALL. Genotype-specific, cooperative, possibly inter-group, protocol studies are needed to develop more effective treatment of MLL (HRX), BCR-ABL, IL3-IGM, HLF-E2A and hypodiploid ALL as well as to learn more about their epidemiology, biology and pathogenesis.
The genotypic classification of ALL presented here can be relatively simple and expeditious. At diagnosis, light microscopy and flow cytometry for lymphoid markers and DNA index can usually define leukemia cell type and determine ploidy. If the ALL is hyperdiploid or hypodiploid, or if T cell or B cell, no further study is required. If the ALL is Bprecursor with a DNA index between 1.0 and 1.16, Southern blot or preferably polymerase chain reaction studies at a central reference laboratory can be used to test for TEL-AML 1, MLL, E2A-PBX or BCR-ABL rearrangements. If the patient has a coagulopathy, HLF-E2A can be tested for, and if eosinophilia with or without carditis, IL3-IGM. If ALL that has trisomy 4 and 10 without hyperdiploidy is to be identified, chromosome analysis without banding can be used. Fluorescent in situ hybridization (FISH) is also a useful tool in genetic classification of leukemia.
As with morphologic and immunophenotypic classification methods, continuous modifications of this genotypic classification will be required with continued advances in technology, recognition of additional significant molecular genetic entities, and identification of downstream targets of the transcription factors coded by many ALL-associated novel fusion genes (Kurosawa H et al, Blood 90: 178a, 1997) . Better understanding of the basis of hyperdiploidy and hypodiploidy in ALL might also modify genotypic classification (Onodera N et al, Blood 80: 203, 1992) .
However, in addition to genotypic classification host factors such as family finances and function, insurance coverage, ethnicity, nutrition, infection, hygiene and proximity to a leukemia treatment center remain important in selection of treatment and interpretation of outcome (Pinkel D, J Clin Oncol 14: 4, 1996) . Age is an important consideration because of the lesser tolerance of newborn and young infants to chemotherapy and the tendency to non-adherence by adolescents. Constitutional genotype can affect treatment plans as exemplified by the lower tolerance of children with Down syndrome to methotrexate (Garre M et al, J Pediatr 111: 606, 1987) . Finally, the importance of genetic polymorphism in chemotherapy is increasingly recognized. For example, children with genetic deficiency of thiopurine methyl transferase require only low doses of mercaptopurine for its efficacy and can experience severe toxicity with conventional dosage (Lennard L et al, Med Ped Oncol 29: 252, 1997) .
